Envista Holdings Corporation (NYSE:NVST) Receives $28.54 Average Price Target from Brokerages

Envista Holdings Corporation (NYSE:NVST) has been assigned an average recommendation of “Hold” from the sixteen brokerages that are currently covering the company, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $28.6154.

Several analysts have weighed in on the company. Citigroup assumed coverage on Envista in a research report on Wednesday, April 15th. They set a “neutral” rating and a $29.00 price objective on the stock. Robert W. Baird increased their target price on Envista from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Barclays lowered their target price on Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, June 11th. Morgan Stanley lifted their price target on Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Finally, Weiss Ratings cut Envista from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 11th.

Institutional Trading of Envista

A number of hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in shares of Envista by 1.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after acquiring an additional 152,488 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after acquiring an additional 1,547,656 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Envista by 15.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after acquiring an additional 444,725 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Envista by 341.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after purchasing an additional 2,210,847 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in Envista by 38.8% in the first quarter. Quantinno Capital Management LP now owns 2,694,970 shares of the company’s stock worth $68,371,000 after purchasing an additional 753,474 shares during the period.

Envista Stock Performance

NYSE:NVST opened at $27.31 on Tuesday. The company has a 50-day moving average price of $25.67 and a 200-day moving average price of $25.94. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of 66.61, a P/E/G ratio of 1.55 and a beta of 0.86. The company has a current ratio of 2.44, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47. Envista has a 12 month low of $18.77 and a 12 month high of $30.42.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Envista had a net margin of 2.41% and a return on equity of 7.11%. The company had revenue of $705.50 million for the quarter, compared to analysts’ expectations of $680.03 million. During the same quarter in the previous year, the company earned $0.24 earnings per share. Envista’s quarterly revenue was up 14.4% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities analysts predict that Envista will post 1.42 EPS for the current year.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.